Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis

Journal of the American College of Cardiology

Volumn 45, Issue 11, 2005, Pages 1832-1839

  Healey, Jeff S ^a,c   Baranchuk, Adrian ^a   Crystal, Eugene ^b   Morillo, Carlos A ^a   Garfinkle, Michael ^b   Yusuf, Salim ^a   Connolly, Stuart J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLYCERYL TRINITRATE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; TRANDOLAPRIL; VALSARTAN;

ARTICLE; CARDIOVERSION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; COMORBIDITY; ELECTRIC COUNTERSHOCK; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 20344396863     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.11.070     Document Type: Article

References (41)

1. R. Garg, S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
2. C.B. Granger, J. McMurray, S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors the CHARM-Alternative Trial Lancet 362 2003 772 776
3. J.G. Cleland, L. Erhardt, G. Murray, A.S. Hall, S.G. Ball Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE study Investigators Eur Heart J 18 1997 41 51
4. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both N Engl J Med 349 2003 1893 1906
5. L. Kober, C. Torp-Pedersen, J.E. Carlsen A clinical trial of the angiotensin converting enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 333 1995 1670 1676
6. B. Dahlof, R.B. Devereux, S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol Lancet 359 2002 995 1003
7. A.H. Madrid, M.G. Bueno, J.M.G. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation Circulation 106 2002 331 336
8. M.P. Van den Berg, H.J.G.M. Crijns, D.J. van Veldhuisen, M. Griep, P.J. De Kam, K.I. Lie Effects of lisinopril in patients with heart failure and chronic atrial fibrillation J Card Fail 1 1995 355 363
9. O.D. Pedersen, H. Bagger, L. Kober, C. Torp-Pedersen Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
10. Val-HeFT. Post-hoc analysis suggests valsartan reduces new AF in patients with heart failure. Presented at: ESC Congress 2003, Clinical Trial Update II: Heart Failure, Presentation #2457; August 30 to September 3, 2003; Vienna, Austria.
11. E. Vermes, J.-C. Tardif, M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction Circulation 107 2003 2926
12. K.C. Ueng, T.P. Tsai, W.C. Yu Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study Eur Heart J 24 2003 2090 2098
13. K. Wachtell, M. Lehto, E. Gerdts Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J Am Coll Cardiol 45 2005 712 719
14. F. Pizzetti, F.M. Turazza, M.G. Franzosi Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction the GISSI-3 data Heart 86 2001 527 532
15. W.B. Kannel, P.A. Wolf, E.J. Benjamin Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation population-based estimates Am J Cardiol 82 1998 2N 9N
16. S.S. Chugh, J.L. Blackshear, W.K. Shen, S.C. Hammill, B.J. Gersh Epidemiology and natural history of atrial fibrillation clinical implications J Am Coll Cardiol 37 2001 371 378
17. I. Moreno, R. Caballero, T. Gonzalez Efectos del irbesartan sobre los canales de potasio responsables de la repolarizacion cardiaca humana Rev Esp Cardiol 55 2002 148
18. Y. Shi, J.-C. Tardif, S. Nattel Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure Cardiovasc Res 54 2002 456 461
19. C.A. Morillo, G.J. Klein, D.L. Jones, C.M. Guiradon Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation Circulation 91 1995 1588 1595
20. F. Ravelli, M. Allessie Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart Circulation 96 1997 1686 1695
21. M.C. Wijffels, C.J. Kirchhof, R. Dorland, M.A. Alessie Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats Circulation 92 1995 1954 1968
22. Y. Shi, A. Ducharme, D. Li, R. Gaspo, S. Nattel, J.C. Tardif Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation Cardiovasc Res 52 2001 217 225
23. D. Li, L. Pang, T.K. Leung, S. Cardin, Z. Wang, S. Nattel Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
24. H. Nakashima, K. Kumagai, H. Urata, N. Gondo, M. Ideishi, K. Arakawa Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation Circulation 101 2000 2612 2617
25. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
26. L. Hansson, L.H. Lindholm, L. Niskanen Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPP) randomised trial Lancet 353 1999 611 616
27. L. Hansson, L.H. Lindholm, T. Ekbom Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study Lancet 354 1999 1751 1756
28. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic JAMA 288 2002 2981 2997
29. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
30. A.A. Alsheikh-Ali, P.J. Wang, W. Rand Enalapril treatment and hospitalization for atrial tachyarrhythmias in patients with left ventricular dysfunction Am Heart J 147 2004 1061 1065
31. K. Swedberg, M. Pfeffer, A. Coen-Solal Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan results from the CHARM study J Am Coll Cardiol 43 Suppl A 2004 222A (abstr)
32. A. De Simone, M. De Pasquale, C. De Matteis Verapamil Plus Antiarrhythmic Drugs Reduce Atrial Fibrillation Recurrences After an Electrical Cardioversion (VEPARAF study) Eur Heart J 24 2003 1425 1429
33. R.E. Schmieder, M.P. Schlaich, A.U. Klingbeil, P. Martus Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 13 1998 564 569
34. T.S. Tsang, M.E. Barnes, K.R. Bailey Left atrial volume important risk marker of incident atrial fibrillation in 1655 older men and women Mayo Clin Proc 76 2001 467 475
35. E.J. Benjamin Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
36. S.M. Vaziri, M.G. Larson, E.J. Benjamin, D. Levy Echocardiographic predictors of nonrheumatic atrial fibrillation the Framingham Heart Study Circulation 89 1994 724 730
37. J. Kalifa, J. Jalife, A.V. Zaitsev Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation Circulation 108 2003 668 671
38. D. Li, S. Fareh, T.K. Leung, S. Nattel Promotion of atrial fibrillation by heart failure in dogs atrial remodeling of a different sort Circulation 100 1999 87 95
39. K.M. Fox European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
40. M.A. Weber, S. Julius, S.E. Kjeldsen Blood pressure dependent and independent effects of anti-hypertensive treatment on clinical events in the VALUE trial Lancet 363 2004 2049 2051
41. K. Teo, S. Yusuf, C. Anderson Rationale, design, and baseline characteristics of 2 large, simple randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) Am Heart J 148 2004 52 61